Johnson and Johnson reported a 100% objective response rate in relapsed/refractory large B-cell lymphoma patients with one prior therapy using its dual CD19/CD20-targeting CAR-T. The therapy demonstrated durable responses and manageable safety, signaling a promising new treatment avenue for aggressive lymphomas.